Retour
Article pour les cliniciens

Avantages et inconvénients du dépistage par mammographie chez les femmes à risque moyen de cancer du sein: une revue systématique pour l'Initiative de la Commission européenne sur le cancer du sein



  • Canelo-Aybar C
  • Ferreira DS
  • Ballesteros M
  • Posso M
  • Montero N
  • Sola I, et al.
J Med Screen. 2021 Dec;28(4):389-404. doi: 10.1177/0969141321993866. Epub 2021 Feb 25. (Review)
PMID: 33632023
Lire le résumé Lire résumé des données probantes Lire le texte intégral
Disciplines
  • Médecine familiale (MF)/Médecine générale (MG)
    Relevance - 7/7
    Intérêt médiatique  - 4/7
  • Médecine interne générale - Soins primaires
    Relevance - 7/7
    Intérêt médiatique  - 4/7
  • Santé publique
    Relevance - 6/7
    Intérêt médiatique  - 4/7
  • Oncology - Breast
    Relevance - 5/7
    Intérêt médiatique  - 3/7

Résumé (en anglais)

OBJECTIVES: Mammography screening is generally accepted in women aged 50-69, but the balance between benefits and harms remains controversial in other age groups. This study systematically reviews these effects to inform the European Breast Cancer Guidelines.

METHODS: We searched PubMed, EMBASE and Cochrane Library for randomised clinical trials (RCTs) or systematic reviews of observational studies in the absence of RCTs comparing invitation to mammography screening to no invitation in women at average breast cancer (BC) risk. We extracted data for mortality, BC stage, mastectomy rate, chemotherapy provision, overdiagnosis and false-positive-related adverse effects. We performed a pooled analysis of relative risks, applying an inverse-variance random-effects model for three age groups (<50, 50-69 and 70-74). GRADE (Grading of Recommendations Assessment, Development and Evaluation) was used to assess the certainty of evidence.

RESULTS: We identified 10 RCTs including 616,641 women aged 38-75. Mammography reduced BC mortality in women aged 50-69 (relative risk (RR) 0.77, 95%CI (confidence interval) 0.66-0.90, high certainty) and 70-74 (RR 0.77, 95%CI 0.54-1.09, high certainty), with smaller reductions in under 50s (RR 0.88, 95%CI 0.76-1.02, moderate certainty). Mammography reduced stage IIA+ in women 50-69 (RR 0.80, 95%CI 0.64-1.00, very low certainty) but resulted in an overdiagnosis probability of 23% (95%CI 18-27%) and 17% (95%CI 15-20%) in under 50s and 50-69, respectively (moderate certainty). Mammography was associated with 2.9% increased risk of invasive procedures with benign outcomes (low certainty).

CONCLUSIONS: For women 50-69, high certainty evidence that mammography screening reduces BC mortality risk would support policymakers formulating strong recommendations. In other age groups, where the net balance of effects is less clear, conditional recommendations will be more likely, together with shared decision-making.


Commentaires cliniques (en anglais)

Family Medicine (FM)/General Practice (GP)

This systematic review did NOT look at all-cause mortality. It is frustrating that mammogram advocates will look at breast cancer mortality as the big outcome when all-cause mortality matters at least as much. In the 50-69 year age range, other major causes of mortality like heart disease are relatively uncommon, so if breast cancer screening "works", it should save lives including all-cause lives. This leaves me uncertain whether to recommend mammography in a perfunctory way or with great enthusiasm.

Oncology - Breast

This manuscript is a systematic review on benefits and harms of breast cancer mammography screening for women at average risk of breast cancer. The authors conclude that for women 50–69, mammography screening reduces BC mortality risk formulating strong recommendations. In other age groups, where the net balance of effects is less clear, conditional recommendations will be more likely, together with shared decision-making. This article provides useful information but most practitioners in my discipline probably already know this. Besides, this systematic review has some limitations, as no RCTs have sufficient statistical power to assess the benefit of screening on BC mortality according to age subgroups.

Voulez-vous savoir ce que lisent les professionnels? Inscrivez-vous pour accéder gratuitement à tous les contenus professionnels.

S'inscrire